-+ 0.00%
-+ 0.00%
-+ 0.00%

Trinity Biotech reports 85% AUC in 750-sample study of enhanced EpiCapture prostate cancer test; commercialization plans advance via New York reference laboratory

Reuters·03/25/2026 13:13:14

Please log in to view news